XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Detail)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
May 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
product_target
$ / shares
shares
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2021
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Accounts receivable     $ 6,938     $ 6,013
Biogen MA, Inc. | Stock purchase agreement            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Number of shares issued in transaction (in shares) | shares   24,420,157        
Sale of stock, price per share (in dollars per share) | $ / shares   $ 9.2137        
Consideration received on transaction   $ 225,000        
Standstill restriction period   3 years        
Standstill restriction, ownership threshold percentage ownership percentage   5.00%        
Collaborative arrangement transaction price   $ 204,600        
Excess consideration received on transaction   79,600        
Collaboration agreement, equity issued   145,400        
Accounts receivable     3,400     2,800
Deferred revenue     146,700     $ 154,000
Recognized portion of equity issued     2,900      
Biogen MA, Inc. | Collaboration And License Agreement            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Consideration received on transaction   204,600        
Proceeds from collaborators $ 125,000 125,000        
Maximum milestone payment receivable   $ 2,400,000        
Number of product targets | product_target   12        
Number of additional product targets | product_target   8        
Target selection period   5 years        
Number of product targets selected | product_target   3        
Research period   7 years        
Maximum number of product targets replaced | product_target   10        
Financial advisory fees         $ 7,000  
Percent of initial recognition   2.00%     2.00%  
Portion of contract asset recognized     4,100      
Amortization     $ 100 $ 100    
Biogen MA, Inc. | Collaboration And License Agreement | Pre-approval milestone            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Maximum milestone payment receivable   $ 925,000        
Biogen MA, Inc. | Collaboration And License Agreement | Sales-based milestone            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Maximum milestone payment receivable   $ 1,500,000